Richard Platt1, Leanne Madre, Robert Reynolds, Hugh Tilson. 1. Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA. richard_platt@harvard.edu
Abstract
PURPOSE: Ensuring that drugs have an acceptable safety profile and are used safely is a major public health priority. The Centers for Education and Research on Therapeutics (CERTs) convened experts from academia, government, and industry to assess strategies to increase the speed and predictive value of generating and evaluating safety signals, and to identify next steps to improve the US system for identifying and evaluating potential safety signals. METHODS: The CERTs convened a think tank comprising representatives of the groups noted above to address these goals. RESULTS: Participants observed that, with the increasing availability of electronic health data, opportunities have emerged to more accurately characterize and confirm potential safety issues. The gain for public health from a highly coordinated network of population-based databases for active surveillance is great and within reach, although operational questions remain. A collaborative network must create a working definition of a safety signal, screening algorithms, and criteria and strategies to confirm or refute a signal once identified through screening. Guidelines are needed for when and how to communicate a signal exists and is being evaluated, as well as the outcome of that evaluation. CONCLUSION: A public-private partnership to create a network of government and private databases to routinely evaluate and prioritize safety questions is in the public interest. Better methods are needed, and a knowledgeable workforce is required to conduct the surveillance and understand how to interpret the results. The international community will benefit from the availability of better methods and more experts. Copyright (c) 2008 John Wiley & Sons, Ltd.
PURPOSE: Ensuring that drugs have an acceptable safety profile and are used safely is a major public health priority. The Centers for Education and Research on Therapeutics (CERTs) convened experts from academia, government, and industry to assess strategies to increase the speed and predictive value of generating and evaluating safety signals, and to identify next steps to improve the US system for identifying and evaluating potential safety signals. METHODS: The CERTs convened a think tank comprising representatives of the groups noted above to address these goals. RESULTS:Participants observed that, with the increasing availability of electronic health data, opportunities have emerged to more accurately characterize and confirm potential safety issues. The gain for public health from a highly coordinated network of population-based databases for active surveillance is great and within reach, although operational questions remain. A collaborative network must create a working definition of a safety signal, screening algorithms, and criteria and strategies to confirm or refute a signal once identified through screening. Guidelines are needed for when and how to communicate a signal exists and is being evaluated, as well as the outcome of that evaluation. CONCLUSION: A public-private partnership to create a network of government and private databases to routinely evaluate and prioritize safety questions is in the public interest. Better methods are needed, and a knowledgeable workforce is required to conduct the surveillance and understand how to interpret the results. The international community will benefit from the availability of better methods and more experts. Copyright (c) 2008 John Wiley & Sons, Ltd.
Authors: Peter M Wahl; Joshua J Gagne; Thomas E Wasser; Debra F Eisenberg; J Keith Rodgers; Gregory W Daniel; Marcus Wilson; Sebastian Schneeweiss; Jeremy A Rassen; Amanda R Patrick; Jerry Avorn; Rhonda L Bohn Journal: Drug Saf Date: 2012-05-01 Impact factor: 5.606
Authors: Ben Y Reis; Karen L Olson; Lu Tian; Rhonda L Bohn; John S Brownstein; Peter J Park; Mark J Cziraky; Marcus D Wilson; Kenneth D Mandl Journal: Drug Saf Date: 2012-05-01 Impact factor: 5.606
Authors: Suraj J Patel; Jack M Milwid; Kevin R King; Stefan Bohr; Arvin Iracheta-Vellve; Arvin Iracheta-Velle; Matthew Li; Antonia Vitalo; Biju Parekkadan; Rohit Jindal; Martin L Yarmush Journal: Nat Biotechnol Date: 2012-01-15 Impact factor: 54.908
Authors: Mònica Sabaté; Juan Fernando Pacheco; Elena Ballarín; Pili Ferrer; Hans Petri; Joerg Hasford; Marieke Wilma Schoonen; Marietta Rottenkolber; Joan Fortuny; Joan-Ramon Laporte; Luisa Ibáñez Journal: BMC Res Notes Date: 2014-03-13